Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Sales | 25,800 | 24,149 | 18,172 | 16,261 | 11,763 |
| Cost of Goods | 2,683 | 766 | 452 | 507 | 273 |
| Gross Profit | 23,117 | 23,383 | 17,720 | 15,754 | 11,490 |
| Operating Expenses | 141,833 | 136,623 | 117,386 | 106,601 | 101,409 |
| Operating Income | -118,033 | -112,474 | -99,214 | -90,340 | -89,646 |
| Other Income | 5,332 | 13,515 | 2,674 | 2,640 | 2,583 |
| Pre-tax Income | -112,701 | -98,959 | -96,540 | -87,700 | -87,063 |
| Income Tax | 293 | 213 | 216 | 126 | 247 |
| Net Income Continuous | -112,994 | -99,172 | -96,756 | -87,826 | -87,310 |
| Net Income | $-112,994 | $-99,172 | $-96,756 | $-87,826 | $-87,310 |
| EPS Basic Total Ops | -1.96 | -1.72 | -1.82 | -1.80 | -1.74 |
| EPS Basic Continuous Ops | -1.96 | -1.72 | -1.82 | -1.80 | -1.74 |
| EPS Diluted Total Ops | -1.96 | -1.72 | -1.82 | -1.79 | -1.74 |
| EPS Diluted Continuous Ops | -1.96 | -1.72 | -1.82 | -1.79 | -1.74 |
| EBITDA(a) | $-117,859 | $-112,489 | $-97,934 | $-88,206 | $-86,210 |